Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln

RTTNews | 166 days ago
Stocktwits
Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln

(RTTNews) - Biogen Inc. (BIIB) and privately-held biotechnology company Human Immunology Biosciences or HI-Bio, announced Wednesday the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.

The proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Biosciences' expertise in immune-mediated indications with Biogen's global development and commercial experience in rare diseases.

Biogen plans to leverage its existing global development and commercialization capabilities in rare disease and its strong scientific expertise in immunology to support the advancement of felzartamab and the HI-Bio pipeline.

The total potential deal value can go up to $1.8 billion, should the felzartamab programs achieve certain development milestones.

In addition to lead program felzartamab, the HI-Bio pipeline includes izastobart/HIB210, an anti-C5aR1 antibody currently in a Phase 1 trial.

Biogen seeks to retain expertise and talent from HI-Bio and establish a San Francisco Bay Area team focused on expanding our efforts in immune-mediated diseases.

Biogen expects to finance the acquisition with cash and may also draw on its revolving credit agreement. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals and is currently anticipated to close in the third quarter of 2024.

The acquisition of HI-Bio is not expected to impact Biogen's previously issued 2024 guidance.

Tags: BIIB
Stocktwits
read more
Biogen Q2 Results Top Estimates; Boosts FY24 Outlook

Biogen Q2 Results Top Estimates; Boosts FY24 Outlook

Biotechnology company Biogen Inc. (BIIB) reported Thursday net income attributable to the company for the second quarter of $583.6 million or $4.00 per share, higher than $591.6 million or $4.07 per share in the prior-year quarter.
RTTNews | 95 days ago
Biogen Q2 Results Top Estimates; Backs FY23 Outlook

Biogen Q2 Results Top Estimates; Backs FY23 Outlook

Biotechnology company Biogen, Inc. (BIIB) reported Tuesday that net income attributable to the company for the second quarter plunged to $591.6 million or $4.07 per share from $1.06 billion or $7.24 per share in the prior-year quarter.
RTTNews | 468 days ago
Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook

Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook

Biotechnology company Biogen Inc. (BIIB) reported Tuesday net income attributable to the company for the first quarter of $387.9 million or $2.67 per share, higher than $303.8 million or $2.06 per share in the prior-year quarter.
RTTNews | 559 days ago
Biogen Q4 Results Top Estimates

Biogen Q4 Results Top Estimates

Biotechnology company Biogen Inc. reported Wednesday that profit for the fourth quarter surged 50 percent from last year, reflecting lower expenses despite a 7 percent revenue growth. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also initiated adjusted earnings and revenue growth guidance for the full-year 2023, in line with estimates.
RTTNews | 628 days ago
Biogen Appoints Christopher Viehbacher As President And CEO

Biogen Appoints Christopher Viehbacher As President And CEO

Biotechnology company Biogen Inc. (BIIB) announced Thursday that its Board of Directors has appointed Christopher Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14. Viehbacher succeeds Michel Vounatsos, who has led the company since 2017.
RTTNews | 725 days ago
Tools
Ekonomisko notikumu kalendārs
Market Hours
Interest Rates
Holidays Calendar
Forex Market
Forex Volatility
Forex Correlation
Streaming Forex News
forex analysis
COT Data
Liquidity
Forex Calculators
Forex Heat Map
Indicators Heatmap
Kopiena
Kopiena
Sistēmas
Most Popular Systems
Stratēģijas
Konkursi
Forex Charts
Komunikācijas apskats
Sentiment Indicator
Apskats
Brokeri
Prop Trading Firms
VPS Services
Signālu provaiders
EA Programming Services
Affiliate Programs
PAMM Broker Services
Rebate Program Services
Trading Platforms
Padomnieki (Expert Advisors)
Crypto Exchanges
Trading Courses
Brokeri
Forex Spreads
Forex Broker Quotes
Forex Broker Swaps
Forex Broker Volume
Forex Broker Promotions Broker News
Platforma
Logrīki
Funkcijas
API
RSS
Stock Portfolio
Affiliate Software
Izvērsta diagramma
Atbalsts
BUJ
Palīdzība
Kontaktēties ar mums
Ziņotas par kļūdu!
Par
Blogs
© 2024 Myfxbook Ltd. All Rights Reserved.
HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.